BlossomHill is a pre-revenue biotech where insiders bought $25.2M (4.532% of market cap) while the shares sit in capitulation-style selling and the latest quarterly loss far exceeded estimates.
Thesis pillars
- Binary Biotech Risk→Stable
- Heavy Insider Buying→Stable
- Widening Quarterly Loss↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Oct 11, 2026
BlossomHill Therapeutics, Inc. (BLSM) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $16.46: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. (Note: Risk dimension 5.9/10 and A.R:R 5.8:1 are different metrics that happen to read the same number here.)
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell... Read more
Sell if holding. Engine safety override at $16.46: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. (Note: Risk dimension 5.9/10 and A.R:R 5.8:1 are different metrics that happen to read the same number here.) Chart setup: RSI 48 mid-range, Bollinger mid-band. Score 5.8/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 17d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — BlossomHill Therapeutics, Inc.
Latest news
- NEWS BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-3 — fiscal.ai Oct 22, 2026 positive
- NEWS BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resi — benzinga Oct 22, 2026 positive
- NEWS BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Fil — benzinga Sep 28, 2026 positive
- NEWS Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40 — benzinga Sep 21, 2026 positive
- NEWS Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40 — benzinga Sep 21, 2026 positive
Generated 2026-10-29T11:08:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.46: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. (Note: Risk dimension 5.9/10 and A.R:R 5.8:1 are different metrics that happen to read the same number here.) Chart setup: RSI 48 mid-range, Bollinger mid-band. Prior stop was $15.31. Score 5.8/10, moderate confidence.
Analyst target: $30.80 (+87.1% upside). Prior stop was $15.31. Stop-loss: $15.31.
Quality below floor (2.9 < 4.0); Value-trap signals (2/5): Margin compression (op margin -39.6%), Material insider selling (22 sells, 0.88% of cap).
BlossomHill Therapeutics, Inc. trades at a P/E of N/A (forward -4.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
11 analysts cover BLSM with a consensus score of 4.3/5. Average price target: $35.
What does BlossomHill Therapeutics, Inc. do?BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that...
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.